ImmunoGen Stock News

RIGL, BWAY, AVDX, IMGN and EAT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2023.

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 16, 2023.:

IMGN, AQST, BUR, GWRE and VECO have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2023.

After reaching an important support level, ImmunoGen (IMGN) could be a good stock pick from a technical perspective. IMGN surpassed resistance at the 20-day moving average, suggesting a short-term bul

Invest in stocks such as Confluent (CFLT), Pinterest (PINS), ICON (ICLR) and ImmunoGen (IMGN) for solid earnings acceleration.

The consensus price target hints at a 40.6% upside potential for ImmunoGen (IMGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat

ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company reiterates its revenue guidance.

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will p

ImmunoGen (IMGN) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.31 per share a year ago.

ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted by the EMA. Rumors suggest that large European pharma companies, including GSK, Sanofi, or Merck,

Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare i

OSCR, IMGN, AFRM, ACVA and SOLO have been added to the Zacks Rank #1 (Strong Buy) List on October 20, 2023.

Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.

MRO, APA, IMGN, RAIL and MFA have been added to the Zacks Rank #1 (Strong Buy) List on October 18, 2023.

Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.